A headache specialist explains how health plans are blocking her patients from accessing combination therapy.
A new group of injectable drugs inhibit a protein thought to trigger migraines, but not all insurance plans cover it -- and many people can’t afford the $575 a month price tag.
When two Boeing 737 Max airplanes crashed within the span of six months of each other, killing 346 people, black box recorders helped investigators find the cause. A similar kind of black box should be available to alert regulators, lawmakers, or the public to deaths due to health insurance company behavior.
This year’s World Brain Day, July 22, is aimed at raising awareness of the most common brain disease in the world: migraine. It affects more than 38 million Americans and is the second leading cause of disability worldwide.
Reaction was generally positive to legislation on surprise medical bills passed out of a House committee on Wednesday.
As a stigmatized, painful disease that disproportionately affects women, migraine has significant negative consequences for individuals, their families, and society as a whole.
People living with migraine often bear a financial burden and can be routinely denied when trying to access treatments, especially the most recently approved class of drugs, CGRPs. I connected with Lindsay Videnieks, the Executive Director of the Headache and Migraine Policy Forum (HMPF) in order to get some answers on what people in the migraine community can do when they’re facing barriers to their migraine treatment.
Patients shouldn’t have to endure debilitating symptoms day after day when there is a medication that could help them. Yet that’s what’s happening in Mississippi to people with migraine.
A recent survey of adult migraine sufferers supports a commonly held belief among physicians that multiple dosing options will lead to an increase in compliance with new migraine medications, according to a study recently published in The Journal of Headache and Pain.
BOSTON, MA – Today, Pioneer Institute released a new report, Looming Challenges for ICER in Assessing the Value of Rare Disease Therapies, that examines why the Institute for Clinical and Economic Review (ICER) and the Quality Adjusted Life Years (QALY) approach to value assessment is particularly ill-suited to assess the cost-effectiveness of orphan and rare disease treatments, which represent a rapidly growing sector of the biopharmaceutical marketplace.
Last May, the Food and Drug Administration (FDA) approved Amgen and Novartis’ Aimovig, the first drug specifically designed to prevent chronic migraines, and offered new hope to the millions of Americans regularly weathering these debilitating headaches. Just months later came two other drugs in its class, Eli Lilly’s Emgality and Teva Pharmaceuticals’ Ajovy.
Click below for PDF version.
I’ve had migraines since I was 12, but in 2015 my attacks got much worse. Without migraine-specific painkillers, my migraines make me queasy and tired, forcing me to go to bed with a freezing wet towel on my head.
“It was so bad. It just wouldn’t quit.” Sara, a new patient, was sitting in my office describing a migraine attack that had led to a recent hospitalization. Except it wasn’t exactly the migraine that led to hospitalization. It was, I found out, an attempted suicide, prompted by the relentless impact of chronic migraine.
It’s that time again. The controversial Institute for Clinical and Economic Review is examining its value framework, the rules and assumptions it uses to analyze new drugs’ cost effectiveness. How, ICER asked, can we improve our approach in 2020 and beyond?
Click below to read paper.